- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/502 - Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
Patent holdings for IPC class A61K 31/502
Total number of patents in this class: 1286
10-year publication summary
|
55
|
72
|
72
|
87
|
103
|
106
|
129
|
155
|
136
|
41
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| AstraZeneca AB | 3042 |
34 |
| MetrioPharm AG | 42 |
32 |
| F. Hoffmann-La Roche AG | 7958 |
24 |
| Amgen Inc. | 3779 |
17 |
| Novartis AG | 11238 |
16 |
| Rigel Pharmaceuticals, Inc. | 613 |
15 |
| The Regents of the University of California | 18943 |
13 |
| KuDOS Pharmaceuticals Limited | 49 |
13 |
| Genentech, Inc. | 3742 |
12 |
| Board of Regents, The University of Texas System | 5370 |
11 |
| The Johns Hopkins University | 5377 |
11 |
| Dana-Farber Cancer Institute, Inc. | 2455 |
11 |
| ChemoCentryx, Inc. | 400 |
10 |
| Daiichi Sankyo Company, Limited | 1829 |
10 |
| Jiangsu Hengrui Medicine Co., Ltd. | 780 |
10 |
| Glaxo Group Limited | 4496 |
9 |
| Bristol-myers Squibb Company | 5080 |
9 |
| Centre National de La Recherche Scientifique | 9632 |
9 |
| Takeda Pharmaceutical Company Limited | 2961 |
9 |
| Mirati Therapeutics, Inc. | 199 |
9 |
| Other owners | 1002 |